mLumiOpto Is a Mitochondrial-Targeted Gene Therapy for Treating Cancer.

Area of Science:

• Oncology
• Molecular Biology
• Gene Therapy

Background:

• Mitochondria play a crucial role in cancer development and progression.
• Targeting cancer cell mitochondria offers therapeutic potential, but effective in vivo strategies are limited.

Purpose of the Study:

• To develop and evaluate mitochondrial luminoptogenetics (mLumiOpto) as a novel gene therapy for cancer.
• To investigate mLumiOpto's ability to induce cancer cell death by disrupting mitochondrial membrane potential.

Main Methods:

• Developed mLumiOpto, a gene therapy involving a blue light-gated channelrhodopsin in the inner mitochondrial membrane and cytosolic nanoluciferase.
• Delivered mLumiOpto genes to cancer cells in vivo using adeno-associated viruses (AAVs) with cancer-specific promoters or targeted exosomes.
• Activated channelrhodopsin via nanoluciferase-induced bioluminescence upon luciferin administration.

Main Results:

• mLumiOpto effectively disrupted mitochondrial membrane potential, leading to cancer cell death.
• Demonstrated significant reduction in tumor burden and cancer cell killing in glioblastoma and triple-negative breast cancer xenograft models.
• Induced an antitumor immune response, evidenced by increased dendritic cell and CD8+ T cell infiltration.

Conclusions:

• mLumiOpto is a promising therapeutic strategy for in vivo cancer treatment by targeting mitochondria.
• This optogenetic approach offers a novel method for inducing cancer cell death and reducing tumor burden.